Luteolin regulation of estrogen signaling and cell cycle pathway genes in MCF-7 human breast cancer cells

International Journal of Biomedical Science

Volumn 7, Issue 2, 2011, Pages 101-111

  Markaverich, Barry M ^a   Shoulars, Kevin ^a,b   Rodriguez, Mary Ann ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epigenetic regulation; Estrogen signaling pathway; Luteolin; Type II 3H estradiol binding site ligand

Indexed keywords

ESTRADIOL; ESTROGEN; HISTONE H4; LUTEOLIN; RNA;

ARTICLE; ASK GENE; CANCER CELL; CCNA2 GENE; CCND1 GENE; CDC2 GENE; CDC20 GENE; CDC25B GENE; CDKN1A GENE; CELL CYCLE; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CREBBP GENE; CTBP2 GENE; DDX5 GENE; EP300 GENE; EPIGENETICS; ESR1 GENE; GENE; GENE EXPRESSION; GENETIC REGULATION; GENETIC TRANSCRIPTION; GRB2 GENE; GSK3B GENE; GTF2H2 GENE; HISTONE ACETYLATION; HNRPD GENE; HUMAN; HUMAN CELL; MAD2L1 GENE; MICROARRAY ANALYSIS; NCOA3 GENE; NCOR1 GENE; NCOR2 GENE; NRAS GENE; NRIP1 GENE; PCK2 GENE; PCNA GENE; PGR GENE; PLK1 GENE; POLR2A GENE; POLR2J2 GENE; PRKDC GENE; PROMOTER REGION; PTTG1 GENE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMARCA4 GENE; TAF5L GENE; TAF9 GENE; TRRAP GENE;

EID: 79959626566     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Markaverich BM, Roberts RR, Alejandro MA, Johnson GA, et al. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J. Steroid. Biochem. 1988; 30 (1-6): 71-78.
2. Markaverich BM, Alejandro MA. Bioflavonoids, Type II [3H]Estradiol Binding Sites and Prostatic Cancer Cell Proliferation. International J. of Oncology. 1997; 11: 1311-1319.
3. Markaverich BM, Vijjeswarapu M, Shoulars K, Rodriguez M, et al. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells. J. Steroid. Biochem. Mol. Biol. 2010; 122 (4): 219-231.
4. Shoulars K, Brown T, Alejandro MA, Crowley J, et al. Identification of nuclear type II [(3)H]estradiol binding sites as histone H4. Biochem. Biophys. Res. Commun. 2002; 5: 1083-1090.
5. Shoulars K, Rodrigues MA, Crowley JR, Turk J, et al. Nuclear type II [3H]estradiol binding sites: a histone H3-H4 complex. J. Steroid. Biochem. Mol. Biol. 2005; 96 (1): 19-30.
6. Shoulars K, Rodriguez MA, Crowley J, Turk J, et al. Reconstitution of the type II [3H]estradiol binding site with recombinant histone H4, J. Steroid. Biochem. Mol. Biol. 2006; 99 (1): 1-8.
7. Markaverich BM, Gregory RR, Alejandro M, Kittrell FS, et al. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth. Cancer Res. 1990; 50 (5): 1470-1478.
8. Markaverich BM, Varma M, Densmore CL, Schauweker TH, et al. Nuclear Type II [3H]Estradiol Binding Sites in MCF-7 Human Breast Cancer Cells: Binding Interactions with 2,6-Bis([3,4-dihydroxyphenyl]-methylene)-cyclohexanone Esters and Inhibition of Cell Proliferation. Internat. J. Oncol. 1994; 4: 1291-1300.
9. Piantelli M, Ricci R, Larocca L, Capelli A, et al. Type II Estrogen Binding Sites in Human Colorectal Carcinoma. J. Clin. Path. 1990; 43: 1004-1006.
10. Piantelli M, Rinelli A, Macri E, Maggiano N, et al. Type II estrogen binding sites and antiproliferative activity of quercetin in human menigiomas. Cancer. 1993; 71 (1): 193-198.
11. Piantelli M, Maggiano N, Ricci R, Larocca LM, et al. Tamoxifen and Quercetin Interact with Type II Estrogen Binding Sites and Inhibit the Growth of Human Melanoma Cells. J. of Investigative Dermatology. 1995; 105 (2): 248-253.
12. Scambia G, Ranelletti F, Benedetti Panici P, Piantelli M, et al. Inhibitory effects of quercetin on OVCA 433 cells and the presence of type II oestrogen binding sites in primary ovarian tumors and cultured cells. Br. J. Cancer. 1990; 62: 942-946.
13. Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, et al. Type II Estrogen Binding Sites in a Lymphoblastoid Cell Line and Growth Inhibitory Effects of Estrogen, Anti-Estrogen and Bioflavonoids. Int. J. Cancer. 1990; 46: 1112-1116.
14. Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, et al. Quercetin Inhibits the Growth of Multidrug-Resistant Estrogen-Receptor Negative MCF-7 Human Breast Cancer Cell Line Expressing Type II Estrogen-binding Sites. Cancer Chemother. Pharmacol. 1991; 28: 255-258.
15. Scambia G, Ranelletti FO, Panici B, Piantelli M, et al. Quercetin Induces Type-II Estrogen-Binding Sites in Estrogen-Receptor-Negative (MDA-MB-231) and Estrogen-Receptor-Positive (MCF-7) Human Breast Cancer Cell Lines. International Journal of Cancer. 1993; 54: 462-466.
16. Markaverich BM, Gregory RR, Alejandro MA, Clark JH, et al. Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites. J. Biol. Chem. 1988; 263 (15): 7203-7210.
17. Markaverich BM, Gregory RR, Alejandro MA, Varma RS, et al. Estrogen regulation of methyl p-hydroxyphenyllactate hydrolysis: correlation with estrogen stimulation of rat uterine growth. J. Steroid. Biochem. 1989; 33 (5): 867-876.
18. Markaverich BM, Schauweker TH, Gregory RR, Varma M, et al. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones. Cancer Res. 1992; 52 (9): 2482-2488.
19. Shoulars K, Rodriguez MA, Thompson T, Markaverich BM. Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin, J.Steroid. Biochem. Mol. Biol. 2010; 118 (1-2): 41-50.
20. Shoulars K, Rodriguez MA, Thompson T, Turk J, et al. Regulation of the nitric oxide pathway genes by tetrahydrofurandiols: microarray analysis of MCF-7 human breast cancer cells. Cancer Lett. 2008; 264 (2): 265-273.
21. Markaverich BM, Shoulars K, Alejandro MA. Nuclear type II [3H] estradiol binding site ligands: inhibition of ER-positive and ER negative cell proliferation and c-Myc and cyclin D1 gene expression. Steroids. 2006; 71 (10): 865-874.
22. Shoulars K, Alejandro M, Thomson T, Markaverich B. Preliminary Identification of Rat Uterine Nuclear Type II [3H]Estradiol Binding Sites as Histone H4. Denver: Colorodo State University. 2001.
23. Li C, Wong W. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. USA. 2001; 98: 31-36.
24. Li C, Wong W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome. Biol. 2001; 2: 32.
25. Jeong JW, Lee K, Kwak I, White L, et al. Identification of Murine Uterine Genes Regulated in a Ligand-Dependent Manner by the Progesterone Receptor. Endocrinology. 2005; 146 (8): 3490-3505.
26. Gunawardena R, Siddiqui H, Solomon D, Mayhew C, et al. Hierrar chical requirement of SWI/SNF in retinoblastoma tumor suppressormediated repression of Plk1. J. of Biological Chemistry. 2004; 279: 29178-29198.
27. Sabah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: Involvement of a cAMP response-like element. PNAS. 1999; 96: 11217-11222.
28. Markaverich BM, Clark JH, Hardin JW. RNA transcription and uterine growth: differential effects of estradiol, estriol, and nafoxidine on chromatin RNA initiation sites. Biochemistry. 1978; 17 (15): 3146-3152.
29. Harvell DM, Richer JK, Allred DC, Sartorius CA, et al. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology. 2006; 147 (2): 700-713.
30. Cicatiello L, Scafoglio C, Altucci L, Cancemi M, et al. A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J. Mol. Endocrinol. 2004; 32 (3): 719-775.
31. Tari AM, Hung MC, Li K, Lopez-Berestein G. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene. 1999; 18 (6): 1325-1332.
32. Reis-Fiho J, Milanez F, Carvalho S, Simpson P, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overepression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Research. 2005; 7R: R1028-1035.
33. Zhang Z, Yamashita H, Toyama T, Sugiura H, et al. NCOR1 mRNA is an independent prognostic factor for breast cancer. Cancer Lett.2006; 237 (1): 123-129.
34. Burwinkel B, Wirtenberger M, Klaes R, Schmutzler RK, et al. Association of NCOA3 polymorphisms with breast cancer risk. Clin. Cancer Res. 2005; 11(6): 2169-2174.
35. Miller D, Leontovich A, Lingle W, Suman V, et al. Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. Modern Pathology. 2004; 17: 756-764.
36. Folgueira MA, Brentani H, Katayama ML, Patrao DF, et al. Gene expression profiling of clinical stages II and III breast cancer. Braz. J. Med. Biol. Res. 2006; 39 (8): 1101-1113.
37. Douglas R, Haddad G. Effect of oxygen deprivation of cell cycle activity: a profile of delay and arrest. J. Applied Physiology. 2003; 94: 2068-2083.
38. Eckerdt F, Strebhardt K. Polo-like kinase 1; target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Research. 2006; 66 (14): 6895-6898.
39. van Vugt M, van de Weerdt B, Vader G, Janssen H, et al. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J. Biological Chemistry. 2004; 279 (35): 36841-36854.
40. Paunesku T, Mittal S, Protic M, Oryhon J, et al. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. International J. Radiation Biology. 2001; 77 (10): 1007-1021.
41. Perucca P, Cazzalini O, Mortusewicz O, Necchi D, et al. Spatiotemporal dynamics of p21CDKN1A protein recruitment to DNA-damage sites and interaction with proliferating cell nuclear antigen. J. Cell Sci. 2006; 119 (Pt 8): 1517-1527.
42. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem. Pharmacol. 2000; 60 (8): 1051-1059.
43. Chatterjee A, Chatterji U. Arsenic abrogates the estrogen-signaling pathway in the rat uterus. Reprod. Biol. Endocrinol. 2010; 8: 80.